lonafarnib has been researched along with Lipodystrophy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Djabali, K; Hartinger, R; Lattanzi, G; Lederer, EM; Schena, E | 1 |
| Gordon, LB; Judge, DP; Michaelis, S; Odinammadu, KO; Shilagardi, K; Tuminelli, K | 1 |
2 other study(ies) available for lonafarnib and Lipodystrophy
| Article | Year |
|---|---|
Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies.
Topics: Adipogenesis; Humans; Lipodystrophy; Mutation; Progeria | 2023 |
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Topics: Child; Enzyme Inhibitors; Fibroblasts; Humans; Lamin Type A; Lipodystrophy; Membrane Proteins; Metalloendopeptidases; Mutation; Progeria; Transferases | 2023 |